The Crypto Cat

People are living longer than ever before, but the quality of those added years has not kept pace. Between 1990 and 2023, global life expectancy climbed by nearly a decade to 73.8 years. Healthy life expectancy grew by only seven, to 63.1. That leaves 10.7 years, on average, spent in poor health, according to the latest Global Burden of Disease study. Musculoskeletal disease is the largest single category behind those years of poor health. Nothing else worldwide takes more time from human healthspan. Osteoarthritis is one of its leading contributors. Our Allocetra program is being developed to address it at the mechanism level, targeting the inflammation and immune dysfunction that drive joint deterioration, aiming to reach patients before the disease has done irreversible damage.

1 in 5 adults in the US has a form of arthritis. That is 53.2 million people, according to the CDC. Osteoarthritis alone accounts for 32.5 million of them, more than any other form of the disease combined. Behind the numbers is a specific population. Arthritis prevalence rises sharply after age 45, and as the older US population grows, the number affected is projected to climb toward 78 million by 2040. Osteoarthritis is one of the leading causes of mobility loss in the country, and one of the top drivers of joint replacement surgery. Despite the scale, the treatment landscape has barely changed in decades. Available options treat the pain, modify activity, and end at joint replacement for advanced disease. Our Allocetra program targets the immune dysfunction behind OA, to reach patients while the joint can still be preserved.

Our quality longevity mission is globally accessible by design. The clinical program is being developed for the hundreds of millions of people living with osteoarthritis worldwide, because the disease does not stop at any border. The economic architecture follows the same principle. Enlivex was listed on the Nasdaq, and its equity was tokenized on @Ondo Global Markets, extending exposure to investors outside the traditional US brokerage system. Both are designed the same way: to reach people, wherever they are.

For a century, osteoarthritis was understood as a wear-and-tear condition. The joint was thought to age like a mechanical part, breaking down with repeated use until nothing could be done. Today, inflammation and immune dysfunction are recognized as core drivers of the disease, with joint deterioration shaped by biological processes that were never on the wear-and-tear map. This changes what is possible. These drivers can be targeted using a therapy, while mechanical wear can only be managed or the joint replaced. Still, for more than 600 million people living with the disease worldwide, there is no approved therapy that alters its course. That is what our quality longevity mission was built to change.

Osteoarthritis does not affect men and women equally. Women account for 60% of osteoarthritis cases worldwide, and the gap widens with each decade from age 40 onward. Knee OA hits women hardest, with prevalence, symptom severity, and progression rates all measurably higher. For years, this pattern went unexplained under a mechanical view of the disease. That framing has changed. OA is now recognized as a disorder driven by chronic low-grade inflammation and immune dysfunction, with hormonal and metabolic factors amplifying the risk in women in particular. Our quality longevity mission is designed to address the disease at the inflammatory and immune level that drives it.

Osteoarthritis is often framed as a condition that takes hold later in life, but its impact can begin decades earlier. Global OA prevalence in working-age adults has more than doubled since 1990, from 147 million cases to 329 million in 2021. By 2040, the projection reaches 362 million. This is the population that carries the productive weight of every economy. When OA impacts it, the effect extends to labor force participation, workplace absenteeism, and long-term disability claims. Our Allocetra clinical program was built for that reality. Our mission is to reach patients before the disease has done irreversible damage to the joint.

By 2050, WHO projects there will be 2.1 billion people aged 60 or older, nearly double the current figure. This is the demographic that carries the highest burden of osteoarthritis, a condition that limits mobility, independence, and quality of life. The Enlivex clinical program is focused on OA because it is one of the leading causes of disability in later life. As the older population doubles by mid-century, the disease’s reach grows with it. Our mission is built around the people most vulnerable to a condition that currently has no approved therapy to modify its course.

Prediction markets offer high-frequency, continuously updating forecasts that have utility far beyond trading. The fifth area: filling gaps in financial market data. For a set of core macroeconomic indicators, including GDP, core CPI, and unemployment, no options market has historically existed. Institutional forecasters and policymakers have relied on periodic surveys and consensus estimates, with no continuously priced source of market-based expectations for these variables. Prediction markets have begun producing exactly that. A Federal Reserve Board working paper documents that prediction market pricing on these indicators is the only market-based, real-time signal currently available for these variables. Enlivex holds the largest institutional position in RAIN, the native asset of @Rain__Protocol, giving shareholders exposure, through a Nasdaq-listed equity, to one of the fastest-growing categories in modern finance.

One-third of people with arthritis over the age of 45 live with depression or anxiety, according to CDC data. The damage caused by osteoarthritis does not stop at the joint. Physical pain limits movement, removing people from their daily lives, which increases isolation and impacts mental health. That combination amplifies how the pain itself is experienced. Research on chronic pain documents this loop as bi-directional. Adults with arthritis report nearly twice as many days of poor mental health per month as those without it. Our Allocetra clinical program is being developed to treat osteoarthritis at its root cause. By targeting the immune dysfunction that drives joint deterioration, it is designed to act before the effects reach mobility, mood, and the life built around both.

A quality longevity mission needs a capital structure that can take it through the full arc of clinical development. Clinical trials run on timelines that do not always align with financing cycles. Raising capital exactly when it is needed, on terms that do not force scientific compromises, is one of the defining challenges in this industry. The Enlivex treasury was built around @Rain__Protocol to give the Allocetra program stability at every stage of development. Anchored to prediction markets, one of the fastest-growing categories in modern finance, it provides the runway for the program to move at the pace the science requires. That is the economic architecture our mission was built on.

How is the Enlivex treasury different from a Bitcoin or Ethereum treasury? Those assets track broad crypto adoption and macro conditions, while RAIN is tied at the protocol level to prediction markets volume, with supply mechanics that tighten as @Rain__Protocol usage grows. This positions Enlivex as a company with concentrated exposure to one of the fastest-growing sectors in modern finance, not a general allocation to digital assets. @OrenHershkovitz walks through the reasoning in the clip below.

The first healthspan-wealthspan company in the world. The Enlivex mission stands on two pillars. The Allocetra clinical program, aimed at closing the healthspan gap for the hundreds of millions of people living with osteoarthritis worldwide. And a corporate treasury anchored to prediction markets, built through the largest institutional position in RAIN, the native token of @Rain__Protocol, giving shareholders public equity exposure to the exponential growth of this category. @OrenHershkovitz, Chief Executive Officer of Enlivex, goes deeper on our dual-strategy approach in the clip below.

An FDA RMAT designation is granted when early clinical data suggests a therapy could address a serious unmet medical need. Allocetra has received that designation for age-related knee osteoarthritis, a condition with no approved therapy that alters its course. Our clinical development program is built on closing this treatment gap. @TechRoundUK covers the full story and why osteoarthritis research is so crucial at the link below.

For millions of people worldwide, osteoarthritis turns healthy aging into the loss of independence, mobility, and quality of life. That is the reality the Enlivex quality longevity mission was built to change, and our recent RMAT designation helps bring that closer.

The FDA has granted Allocetra RMAT designation for age-related knee osteoarthritis. This follows Phase I/IIa clinical data showing that Allocetra produced statistically significant and clinically meaningful improvements in knee pain and physical function compared with placebo, durable for at least 6 months. The status enables intensive early engagement with the FDA across the Phase IIb program and creates eligibility for accelerated approval and priority review. More than 370 million people worldwide are living with knee osteoarthritis, and there is no approved therapy that can change the course of the disease. The Allocetra clinical program was built for that gap. This is a step toward closing it.

More than 600 million people are living with osteoarthritis worldwide, according to Global Burden of Disease data. By 2050, that number is projected to approach one billion. It is the most common driver of mobility loss in older adults. It can remove the ability to exercise, maintain weight, stay socially active, and live independently. The downstream effects reach almost every other dimension of quality longevity. And the condition driving this cascade has no approved therapy that modifies it. Current options largely manage symptoms, with surgery often becoming the endpoint for advanced disease. That is why osteoarthritis is where our quality longevity mission begins.

A 1-for-15 reverse stock split of Enlivex ordinary shares takes effect on July 9, 2026. Every fifteen shares will combine into one, reducing the outstanding count from approximately 252 million to roughly 16.8 million. Trading continues on The Nasdaq Capital Market under the ticker ENLV, on a split-adjusted basis. This does not change any shareholder's ownership percentage or voting rights.